moxonidine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 1 studies
moxonidine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with moxonidine, NDDCT and TBZ significantly attenuated 3-NPA induced reduction in body weight, locomotor activity, grip strength, anxiety as well as impaired learning and memory." | 1.40 | Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. ( Gupta, S; Sharma, B, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, S | 1 |
| Sharma, B | 1 |
1 other study available for moxonidine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Brain; Disease Models, Animal; Ditiocarb; Huntington | 2014 |